全文获取类型
收费全文 | 15023篇 |
免费 | 830篇 |
国内免费 | 148篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 322篇 |
妇产科学 | 225篇 |
基础医学 | 1695篇 |
口腔科学 | 377篇 |
临床医学 | 1305篇 |
内科学 | 4738篇 |
皮肤病学 | 179篇 |
神经病学 | 1482篇 |
特种医学 | 603篇 |
外科学 | 2149篇 |
综合类 | 26篇 |
预防医学 | 494篇 |
眼科学 | 132篇 |
药学 | 649篇 |
中国医学 | 9篇 |
肿瘤学 | 1520篇 |
出版年
2023年 | 126篇 |
2022年 | 213篇 |
2021年 | 408篇 |
2020年 | 283篇 |
2019年 | 346篇 |
2018年 | 408篇 |
2017年 | 329篇 |
2016年 | 404篇 |
2015年 | 428篇 |
2014年 | 591篇 |
2013年 | 798篇 |
2012年 | 1145篇 |
2011年 | 1198篇 |
2010年 | 662篇 |
2009年 | 685篇 |
2008年 | 1054篇 |
2007年 | 1120篇 |
2006年 | 1023篇 |
2005年 | 989篇 |
2004年 | 980篇 |
2003年 | 799篇 |
2002年 | 722篇 |
2001年 | 100篇 |
2000年 | 68篇 |
1999年 | 99篇 |
1998年 | 118篇 |
1997年 | 122篇 |
1996年 | 89篇 |
1995年 | 81篇 |
1994年 | 61篇 |
1993年 | 74篇 |
1992年 | 47篇 |
1991年 | 57篇 |
1990年 | 39篇 |
1989年 | 24篇 |
1988年 | 27篇 |
1987年 | 29篇 |
1986年 | 37篇 |
1985年 | 24篇 |
1984年 | 29篇 |
1983年 | 23篇 |
1982年 | 17篇 |
1981年 | 15篇 |
1980年 | 15篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1972年 | 8篇 |
1968年 | 7篇 |
1967年 | 10篇 |
1966年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 24 毫秒
991.
Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial 总被引:22,自引:0,他引:22
Bassi C Falconi M Molinari E Mantovani W Butturini G Gumbs AA Salvia R Pederzoli P 《Surgery》2003,134(5):766-771
BACKGROUND: Anastomotic failure is still a significant problem that affects the outcome of pancreaticoduodenectomy. There have been many techniques proposed for the reconstruction of pancreatic digestive continuity, but there have been few prospective and randomized studies that compare their efficacy. METHODS: In the current work, 144 patients who underwent a pancreaticoduodenectomy with soft residual tissue were assigned randomly to receive either a duct-to-mucosa anastomosis (group A) or a 1-layer end-to-side pancreaticojejunostomy (group B). RESULTS: The 2 treatment groups were found not to have any differences in regards to vital statistics, underlying disease, or operative techniques. The postoperative course was complicated in 54% of the 144 patients, with a comprehensive incidence of abdominal complications in 36% (group A, 35%; group B, 38%; P=not significant). The principal complication was pancreatic fistulas, which occurred in 14% of patients (group A, 13%; group B, 15%; P=not significant). Two patients (2%) required reoperation; the postoperative mortality rate was 1%. CONCLUSION: The 2 methods that were studied revealed no significant difference the rate of complications. 相似文献
992.
Gebbia V Galetta D Caruso M Verderame F Pezzella G Valdesi M Borsellino N Pandolfo G Durini E Rinaldi M Loizzi M Gebbia N Valenza R Tirrito ML Varvara F Colucci G;Gruppo Ocologico Italia Meridionale 《Lung cancer (Amsterdam, Netherlands)》2003,39(2):179-189
PURPOSE: we carried out a phase III randomized trial to compare vinorelbine-cisplatin regimen to gemcitabine-cisplatin regimen, and to a sequential administration of gemcitabine-ifosfamide followed by vinorelbine-cisplatin or the opposite sequence of vinorelbine-cisplatin followed by ifosfamide-gemcitabine according to the 'worst drug rule' hypothesis in patients with locally advanced unresectable stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoint was survival parameters, while secondary endpoints included analysis of response rates and toxicity. PATIENTS AND METHODS: patients were randomized to receive: (a) gemcitabine 1000 mg/m(2) on days 1, 8 and 15 plus ifosfamide 1500 mg/m(2) on days 8-12 with mesna uroprotection (GI regimen) followed by vinorelbine 25 mg/m(2) on days 1 and 8 plus cisplatin 100 mg/m(2) on day 1 (GI --> VC regimen); (b) the opposite sequence (VC --> GI); (c) vinorelbine plus cisplatin as above described (VC regimen); or (d) gemcitabine 1400 mg/m(2) on days 1 and 8 plus cisplatin 100 mg/m(2) on day 8 (GC regimen). All regimens were given every 4 weeks. All patients were chemotherapy naive and had a ECOG PS 0-2. RESULTS: 400 patients were enrolled into the trial. Interim analysis after inclusion of 243 patients showed that ORR were 19% in the GI --> VC arm, 32% in the inverse sequence arm (CV --> GI), 42% in the VC arm, and 30% in the GC arm. The VC arm was statistically superior over the GI --> VC arm (p = 0.0074), but not over the other regimens. Median TTP was 3.1 months in the GI --> VC arm versus 5.0 months in the VC --> GI arm (p = 0.014). For these reasons the GI --> VC and VC --> GI arm were closed since the 'worst drug rule' hypothesis was rejected. Accrual in the VC and GC arms continued up to 140 and 138 patients respectively. Final ORR were 44% for the VC regimen (4 CR), and 34% for the GC regimen (1 CR). This difference was statistically significant (p = 0.032). OS was 9.0 and 8.2 months, respectively, with no statistically significant difference. The 1-year survival rate was 24 and 20%, respectively for VC and GC regimens. As expected the incidence of phlebitis was higher in the VC arm, while thrombocytopenia, flu-like syndrome and asthenia were more frequent in the GC arm. CONCLUSIONS: the results of this trial indicate that the combination of vinorelbine and cisplatin and that of gemcitabine and cisplatin are equivalent in terms of median TTP and OS, although the vinorelbine-cisplatin regimen is associated with a higher ORR. Both regimens may be considered as reference treatments for future studies. Moreover, our data reject the 'worst drug rule' hypothesis of sequential treatments in NSCCL at least with the combination used in this study. 相似文献
993.
Libra M Sorio R Buonadonna A Berretta M Stefanovski P Toffoli G Mazzaglia G Cordani N Stivala F Boiocchi M 《Tumori》2003,89(3):311-313
Platinum-based therapy is considered the standard treatment for patients with advanced ovarian cancer. Carboplatin has a more favorable toxicity profile than cisplatin; however, hypersensitivity reactions to carboplatin have been reported occasionally. We reviewed 112 cases of ovarian cancer treated with carboplatin at our institute to identify the hypersensitivity reactions to this chemotherapeutic agent. Hypersensitivity reactions were documented in nine cases (8%). No deaths occurred, but the reactions were judged severe in three of the 112 patients (2.6%). In our own experience with patients showing idiosyncrasy to carboplatin we observed successful resolution after retreatment with cisplatin. Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment. 相似文献
994.
Martino M Morabito F Console G Irrera G Messina G Pucci G Nardi M Nobile F Molica S Cicero G Palazzo S Peta A Musolino C Iacopino P 《Tumori》2003,89(4):385-390
Multiple factors contribute to transplant-related complications after high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation, including conditioning regimens, number of infused stem cells and clinical characteristics of patient at transplant. We compared the transplant-related complications of 141 patients affected with hematological malignancies with those of 109 patients with solid tumors. The total number of peripheral blood stem cell transplantations performed was 339. High-dose chemotherapy mainly consisted of melphalan-, busulphan- or thiotepa-based regimens. Despite the equal number of infused CD34+ cells, patients with a hematological malignancy showed a slower absolute neutrophil count (days to neutrophils > 0.5 x 10(9)/L, 10.6 +/- 3.6 for hematological malignancies versus 9.1 +/- 1.2 for solid tumors, P < 0.0001) and platelet recovery (days to platelets > 20 x 10(9)/L, 16.4 +/- 9.8 for hematological malignancies versus 12.3 +/- 4.1 for solid tumors, P < 0.0001) than patients with a solid tumor. A significantly higher requirement of red blood cell (3.3 +/- 4.1 versus 2.0 +/- 1.9, P < 0.0029) and platelet units (7.5 +/- 10.4 versus 4.2 +/- 3.4, P < 0.0001) was observed for hematological malignancies than for solid tumors. Five graft failures were documented exclusively in patients with a hematological malignancy. Moreover, such patients displayed a longer duration of mucositis (P < 0.0028) and hospital stay (P < 0.0001), but no difference was observed in terms of febrile episodes. Transplant-related mortality was similar between the two groups. In conclusion, patients with a hematological malignancy overall have more complications than those with a solid tumor. 相似文献
995.
Hospital acquired blood stream infection by Ralstonia pickettii in 9 cancer patients related to the heparin solution contamination used to flush the central venous catheter. 相似文献
996.
Pacini S Gulisano M Peruzzi B Sgambati E Gheri G Gheri Bryk S Vannucchi S Polli G Ruggiero M 《Cancer Detection and Prevention》2003,27(5):327-332
Human skin fibroblasts were exposed to 0.2 T static magnetic field generated by a magnetic resonance tomograph. After 1h exposure, cell morphology was modified in association with a concomitant decrease in the expression of some sugar residues of glycoconjugates. Study of cell proliferation and mitogenic signal transduction showed a decrease of thymidine incorporation and of second messenger formation. However, cell viability, assessed by colony forming assay, was unaffected. These results demonstrate that the static magnetic field generated by routinely used magnetic resonance tomograph induces alterations on human skin fibroblasts. 相似文献
997.
Cascinu S Catalano V Piga A Mattioli R Marcellini M Pancotti A Bascioni R Torresi U Silva RR Pieroni V Giorgi F Catalano G Cellerino R 《Cancer investigation》2003,21(5):701-707
Adjuvant 5-fluorouracil (5FU) and levamisole (Lev) have been considered standard treatment for stage III colon cancer patients. However, the uncertain contribution of Lev to the efficacy of treatment has led many oncologists to prefer the 5FU/leucovorin combination. To establish the role of Lev, we conducted a randomized trial comparing the 5FU/Lev combination with 5FU alone in patients with Dukes' C colon cancer. Patients with stage III colon cancer were randomized to receive 5FU alone (450 mg/m2 IV bolus daily for 5 days and then, beginning at day 28, weekly for 48 weeks) or the same plus Lev (50 mg orally three times/day for 3 days, repeated every 2 weeks for 1 year). From December 1994 to March 1998, 92 patients were assigned to receive 5FU/Lev, and 93 were assigned to receive 5FU alone. Leukopenia and hepatic toxicity were more frequent in patients receiving 5FU/Lev as compared with those receiving 5FU (respectively, p=0.003 and p=0.039), whereas other toxicities were equivalent and mild in both arms. After a median follow-up time of 48 months, 80 patients have had recurrences (40 in each arm) and no advantages in terms of disease-free survival and overall survival could be demonstrated for the combination arm. The addition of Lev to 5FU does not seem to be relevant for the clinical activity of this adjuvant regimen, whereas toxicity related to Lev should be considered when an adjuvant treatment for stage III colon cancer patients is proposed. 相似文献
998.
999.
Luteinizing hormone increases human endometrial cancer cells invasiveness through activation of protein kinase A 总被引:4,自引:0,他引:4
Dabizzi S Noci I Borri P Borrani E Giachi M Balzi M Taddei GL Marchionni M Scarselli GF Arcangeli A 《Cancer research》2003,63(14):4281-4286
Endometrial cancer (EC) is a hormone-dependent cancer that currently represents the most frequent malignancy of the female reproductive tract. The involvement of steroid hormones in its etiology and progression has been reported. The possibility that even gonadotropins (GT) could play a role in the genesis and establishment of EC is supported by the fact that specific receptors for the GT luteinizing hormone/human chorionic GT (LH/hCG) have been detected in a high percentage of ECs, and their expression is apparently related to the cancer grading. However, the precise mechanisms by which GTs might exert their effect on EC is still obscure. The aim of this study was to determine the effects of LH/hCG on the invasion potential of EC cell lines and primary human EC cells. Human recombinant (hr) LH (and hCG) induced a significant increase in cell invasiveness through Matrigel-coated porous membranes in an EC human cell line Hec1A, which expresses the LH/hCG receptor. This effect turned out to depend on hrLH binding to its specific receptors and to the subsequent activation of protein kinase A (PKA). Moreover the hrLH-induced increase in Hec1A invasiveness relied upon a PKA-dependent functional activation of beta(1) integrin receptors, as well as the subsequent induction of matrix metalloproteinase-2 secretion in its active form. The same mechanisms were also found to be operative in primary EC cells. In fact, a significant percentage of primary ECs expressed the LH/hCG receptor, and hrLH addition to primary EC cells, which expressed the specific receptors produced an increase in cell invasiveness only in those tumor cells possessing the specific receptors. This effect was also dependent on PKA activity. We conclude that LH/hCG can regulate EC cells invasiveness, and this result provides a rationale for the use of inhibitors of LH secretion such as GnRH analogues in the treatment of EC. 相似文献
1000.
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? 总被引:4,自引:0,他引:4